Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, acne, rosacea, and psoriasis; and central nervous system, cardiovascular, and gastrointestinal diseases. Its strategic brands include ACTIKERALL, BALNEUM, DECODERM, SATIVEX, SKILARENCE, and DECODERM. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain. GBP drops as BOE vote split seems dovishThe BOE has left rates unchanged in December but a more dovish vote split has weighed on the pound.
13:15, 19 December 2024
A hawkish Fed cut sparks fresh volatilityDiscover how the Federal Reserve's hawkish stance, revised SEP, and delayed inflation targets triggered market volatility, with stocks tumbling, bond yields surging, and a stronger US Dollar reshaping investor outlooks.
12:46, 19 December 2024
Gold Latest: XAU/USD stuck within range ahead of the FOMC meetingGold traders await the FOMC meeting to determine how many rate cuts to expect in 2025.
11:25, 18 December 2024
GBP/USD in focus ahead of FED and BOE meetings Both the Federal Reserve and Bank of England will deliver their updated monetary policies this week, with GBP/USD likely to experience increased momentum.
17:33, 17 December 2024